Cancer Biomarker Studies Retracted

Researchers from Johns Hopkins University School of Medicine have retracted two papers involving colon cancer biomarkers.

By | January 3, 2013

A micrograph of a mucinous adenocarcinoma of the colon, a type of colon cancer.WIKIMEDIA, NEPHRONAlleged inconsistencies and data falsification have led to the retraction of two papers on colon cancer biomarkers, according to Retraction Watch. These papers are the third and fourth yanked from the literature for the research group, formerly at Johns Hopkins School of Medicine.

One of the papers, on new biomarkers for colorectal cancer, was pulled from the March 1, 2008, issue of Clinical Cancer Research, after being cited 21 times, according to ISI. “The authors feel that the inconsistencies in the data collection and recordation warrant retraction of the article,” the coauthors of the paper wrote in the retraction notice. “Five of the 6 authors of the original article agreed to this Retraction,” they noted. “Attempts on the part of the journal office to contact the first author, Eddy S. Leman, were unsuccessful.”

Leman was also lead author on the second paper, published in the June 15, 2007, issue of Cancer Research and cited 31 times, according to ISI. That paper, on other novel colorectal cancer biomarkers, was retracted for similar reasons, according to the published notice announcing its withdrawal from the journal.

Leman did not sign off on either retraction, apparently because his coauthors and the journals in question were unable to establish contact with him. These two retractions bring the total to four for the group, which comprised researchers at Johns Hopkins and the University of Pittsburgh. The two earlier retractions involved papers on prostate cancer, and all four studies, were publicly criticized by University of Toronto biochemist Eleftherios Diamandis for containing suspect methodologies.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech